Nexstim continues to report promising results in quickly growing number of patients completing SmartFocus® rTMS treatment of Major Depressive Disorder
Helsinki, Finland: 5 October 2020 – Nexstim Plc (NXTMH:HEX, NXTMS:STO) reports very promising clinical outcomes of the 108 patients who have completed Nexstim SmartFocus® rTMS treatment with Nexstim NBT® system for major depressive disorder (MDD).
Treatment outcomes of these 108 patients were good: 42 % were in remission at end of treatment and 74 % obtained a clinical response.
These outcomes are clearly higher than what is usually reported for MDD: In a well-conducted multisite study, remission rates were 26.5-28.7 % and the patient-reported response rates were 41.5-56.4 % 1).
The clinical outcomes of majority of the patients treated with SmartFocus® rTMS in the United States are being collected in a registry — the information is provided by participating clinical sites using Nexstim’s SmartFocus® technology.
The number of patients who are being treated with Nexstim SmartFocus® rTMS is growing fast. This can also be seen in the data registry where over 230 patients in total have been enrolled in.
According to the registry, average general impression of receiving the SmartFocus® rTMS treatment reported by the patients completed the treatment was very positive with a mean score of 8.81 on a scale from 0 to 10 (10= best possible).
Further information on Nexstim’s website.